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Aims:We have compared the endothelin receptor subtype afﬁnity (KD) and selectivity of four structural clas-
ses of antagonists (peptide, sulphonamide-based, carboxylic acid-based, myceric acid-based) in human car-
diovascular tissues to determine whether these are predicted by values reported for human cloned receptors.
Additionally, afﬁnities (KB) for these antagonists, determined in ET-1-mediated vasoconstriction assays in
human blood vessels, were used to identify discrepancies between KB and KD determined in the same tissues.
Main methods: Competition binding experiments were carried out in sections of human left ventricle, coro-
nary artery and homogenates of saphenous vein to determine KD values for structurally different ETA-selective
(FR139317, BMS 182874, S97-139, sitaxentan, ambrisentan) and mixed (PD142893, Ro462005, bosentan,
L-749329, SB209670) antagonists. Schild-derived values of antagonist afﬁnity were obtained in vascular
functional studies.
Key ﬁndings: When compared with previously reported data in human cloned endothelin receptors, those
antagonists reported to be ETA-selective exhibited even greater ETA selectivity in human ventricle (BMS
182874, sitaxentan, ambrisentan) that expressed both receptor subtypes. Those antagonists reported to
have b100 fold selectivity in cloned receptors (PD142893, Ro-462005, bosentan, SB209670, L-749329)
did not distinguish between receptor subtypes in human left ventricle. For antagonists where we deter-
mined afﬁnity in vascular functional and binding assays (Ro462005, bosentan, BMS 182874, L-749329,
SB209670) there was no correlation between the degree of discrepancy in KB and KD and structural class.
Signiﬁcance: For an antagonist to retain ETA-selectivity in vivo it may be necessary to identify those com-
pounds that have at least 1000 fold ETA:ETB selectivity in in vitro assays.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The endothelins (ETs) are a family of three endogenous twenty-
one amino acid peptides, ET-1, ET-2 and ET-3 (Inoue et al., 1989;
Yanagisawa et al., 1988) that mediate their action via two G-protein
coupled receptors, ETA (Arai et al., 1990; Hosoda et al., 1992) and
ETB (Sakurai et al., 1990). In the human vasculature ET-1, released
from endothelial cells acts on the ETA receptors that predominate
on the underlying smooth muscle cells throughout the human cardio-
vascular system and mediate vasoconstriction. In some vessels a
small population of ETB receptors (usually b15%) are also present
and these may also mediate constriction (Davenport and Maguire,
1994; Maguire and Davenport, 1995) although infusion of the ETA se-
lective peptide antagonist, BQ-123, into healthy volunteers caused
progressive vasodilatation (Haynes and Webb, 1994), consistentUnit, Level 6 ACCI, Box 110
+44 1223 762579; fax: +44
guire).
Y-NC-ND license.with ET-1 being continuously released to cause vasoconstriction via
this subtype. In contrast infusion of an ETB selective antagonist,
BQ788, caused systemic vasoconstriction, showing that the main con-
sequence of activation of endothelial ETB receptors by tonically se-
creted ET-1 was release of nitric oxide (Love et al., 2000). The ETB
receptor also functions as a clearing receptor, to internalise the
ligand-receptor complex and remove ET-1 from the circulation
(Fukuroda et al., 1994; Gasic et al., 1992; Plumpton et al., 1996). As
a result the plasma half life of ET-1 is comparatively short. ETB receptors
are expressed at particularly high densities in human lung, kidney and
liver (Davenport and Russell, 2001; Gariepy et al., 2000; Kuc et al., 1995).
Overproduction of ET in pathophysiological conditions may lead
to vasospasm, particularly in conditions of endothelial dysfunction
where there is loss of counter regulatory vasodilators such as nitric
oxide, prostacyclin and endothelium derived hyperpolarising factor.
Endothelin is thought to contribute to processes associated with vas-
cular remodelling such as smooth muscle cell proliferation, ﬁbrosis
and inﬂammation. Antagonists that block the endothelin receptors
either selectively or non-selectively were originally developed for the
treatment of heart failure. Clinical trial data were disappointing in this
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compound bosentan (Tracleer) (Rubin et al., 2002) and the ETA antago-
nist ambrisentan (Letairis, Volibris) (Vatter and Seifert, 2006) have
been introduced for treatment of pulmonary arterial hypertension
(PAH). The more ETA selective antagonist sitaxentan (Thelin) (Benza
et al., 2007; Galie et al., 2009) was recently withdrawn voluntarily
from the market. Although endothelin receptor antagonists have be-
come established as having therapeutic beneﬁt in PAH (Liu et al.,
2009; McLaughlin et al., 2009), the relative merits of mixed ETA/ETB or
selective ETA antagonism continue to be debated (Davie et al., 2009;
Dupuis and Hoeper, 2008; Vachiery and Davenport, 2009). Many of
the detrimental actions of ET-1 are thought to result from the activation
of the ETA receptor that predominates in human vascular smooth
muscle and mediates vasoconstriction. Beneﬁcial actions result from
stimulation of the ETB receptor and include vasodilatation, clearing ET
from the circulation, diuresis and natriuresis (Davenport and Maguire,
2006). New clinical indications for ET antagonists are emerging, including
chronic kidney disease (Karet and Davenport, 1996; Goddard et al., 2004;
Karet et al., 1993; Kohan, 1997, 2010; Longaretti and Benigni, 2009;
Neuhofer and Pittrow, 2009) autoimmune disorders of the vasculature
such as scleroderma (Abraham and Dashwood, 2008) and remarkably
in cancer (Bagnato et al., 2008; Bhalla et al., 2009; Growcott, 2009).
In order to determine the relative beneﬁt of mixed ETA/ETB compared
to ETA-selective blockade in these conditions it is important to quantify
the endothelin receptor selectivity of antagonists. For the most part
this has been achieved using human cloned receptors or cells/animal
tissues that endogenously express only (or predominantly) one or
other receptor subtype. We were interested to know how closely
these data predict the afﬁnity and selectivity of antagonists for human
receptors expressed in clinically relevant human tissues. We have pre-
viously determined afﬁnity of a number of antagonists in radioligand
binding assays using human heart or blood vessels and carried out func-
tional experiments on some of these compounds to determine their
ability to antagonise ET-1 mediated vasoconstriction in human artery
and vein. We have now extended these studies to provide additional
data for antagonists from each of four different chemical classes
(Palmer, 2009): the peptide PD142893; the sulphonamides Ro462005,
bosentan, BMS 182874, L-749329 and sitaxentan; the carboxylic
acids SB209670 and ambrisentan and the myceric acid S97-139.
Our aim was to compare the afﬁnity of these ET receptor antagonists
obtained in our pharmacological binding and functional assays using
human tissue together with values that we have previously reported
for other antagonists in these four classes to values reported in




Anonymised human cardiovascular tissue samples were used in
this study with local ethical approval (REC 05/Q0104/142). The sam-
ples were obtained from Papworth Hospital Research Tissue Bank
(Cambridgeshire 1 Research Ethics Committee reference 08/H0304/
56, samples collected with written informed patient consent). Unless
otherwise stated n-values refer to the number of patients from whom
tissue was obtained.
Competition binding assays in human cardiovascular tissues
The binding experiments were performed in the presence of bovine
serum albumin (BSA) to more closely reﬂect in vivo conditions, as some
of these compounds are known to show appreciable binding to plasma
proteins (Wu-Wong et al., 1996). Competition binding experiments
were carried out as previously described (Davenport and Kuc, 2005;
Davenport et al., 1995; Maguire et al., 1996). Brieﬂy, sections of humanheart (10 μm), coronary artery (10 μm) or homogenates of saphenous
vein (Maguire et al., 1996) were pre-incubated in HEPES buffer
and then with [125I]ET-1 (0.1 nM) for 2 h at room temperature in the
presence of increasing concentrations of antagonists (2 pM–100 μM).
Non-speciﬁc binding was determined in the presence of 1 μM of the
unlabelled ligand. Afﬁnities (KD the equilibrium dissociation constant)
of antagonists for ETA and ETB receptors were determined using the
non-linear curve ﬁtting programme KELL (Biosoft, http://Biosoft.com).
For each antagonist data were obtained in tissue from at least three
individuals.
Human vasoconstriction functional assay in human artery and vein
Experiments were carried out as previously described (Maguire,
2002). Brieﬂy, 4 mm rings of endothelium-denuded human coronary
artery or saphenous vein were set up for isometric force recordings.
Cumulative CRCs were constructed to ET-1 (10−10–10−6 M) in the
absence (control) and presence of three or four concentrations of
each antagonist. Blood vessel preparations were incubated with an-
tagonists for 30–40 min prior to addition of ET-1. Experiments were
terminated by the addition of 100 mM KCl to determine the maxi-
mum possible vasoconstrictor response for each tissue and ET-1 re-
sponses were expressed as a % of this terminal KCl response. Data
were analysed using the non-linear iterative curve-ﬁtting programme
FigSys (Biosoft) and antagonist afﬁnities (KB the equilibrium dissoci-
ation constant) were determined by Schild analysis (Arunlakshana
and Schild, 1959). If not signiﬁcantly different from one, Schild slopes
were constrained to one to determine the value of KB. For each con-
centration of antagonist data were obtained in vascular tissues from
3 to 10 individuals.
Materials
ET-1was from The Peptide Institute (Osaka, Japan). Sitaxentanwas
a gift from Pﬁzer Inc., ambrisentan was a gift from Gilead Sciences Inc.
Other antagonists were kindly supplied by Parke-Davis. [125I]-ET-1
(2200 Ci/mmol) was from PerkinElmer NEN® Radiochemicals.
Results
Selectivity of endothelin receptor antagonists determined in human left
ventricle
Peptide antagonists: In human left ventricle the modiﬁed peptide
PD142893 exhibited four-fold selectivity for the ETA receptor (ETA KD
0.30±0.03 μM; ETB KD 1.17±0.14 μM).
Sulphonamide antagonists: BMS 182874 was found to have high
nanomolar afﬁnity for the ETA receptor (KD 590±100 nM)but no detect-
able afﬁnity for the ETB receptor. Sitaxentanwas also highly ETA selective
(ETA KD 1.65±0.80 nM; ETB KD 327±134 μM)whereas a one site ﬁt was
preferred for L-749329 (KD 303.5±34.3 nM) indicating that this com-
pound could not distinguish between the two receptor subtypes.
Carboxylic acid antagonists: Ambrisentan had high afﬁnity for the
ETA receptor and almost 1000 fold selective for this subtype over the
ETB receptor (ETA KD 0.28±0.23 nM; ETB KD 0.25±0.05 μM).
Myceric acid antagonists: S97-139 (ETA KD 45.3±25 nM; ETB KD
47.6±9.9 μM) was 1000 fold selective for the ETA receptor in
human heart.
Afﬁnity of antagonists for the ETA receptor determined in saphenous vein
binding experiments
Peptide antagonists: In human saphenous vein homogenate the
ETA receptor comprises 85% of the total ET receptor population
(Davenport et al., 1995). The peptide FR139317 competed with high
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able afﬁnity for the low density ETB receptor.
Sulphonamide antagonists: A one-site ﬁt was preferred for
Ro462005 (KD 0.15±0.01 μM) and bosentan (KD 32.2±3.2 nM)
which competed for 100% of the [125I] ET-1 binding whereas L-749329
(ETA KD 66.7±7.5 nM) and BMS 182874 (ETA KD 580±40 nM) com-
peted for 85–90% of [125I] ET-1 binding but afﬁnities for the small ETB
population could not be measured.
Carboxylic acid antagonists: SB209670 competed for all of the
[125I] ET-1 binding with a KD of 11.2±1.4 nM.
Afﬁnity of antagonists for the ETA receptor determined in saphenous vein
and coronary artery functional experiments
For all of the antagonists tested, the Schild slopes were not signif-
icantly different from one and therefore slopes were constrained to
one to obtain values of KB.
Peptide antagonists: The Schild-derived afﬁnity for antagonism
of ET-1 by PD142893 (3, 10 30 μM) in saphenous vein was KB of
5.96±0.13 (slope=0.64±0.34, n=3–6) and in coronary artery
(1, 3, 10 μM) KB was 5.83±0.10 (slope=0.67±0.22, n=4–7).
Sulphonamide antagonists: Afﬁnities for Ro462005, bosentan,
BMS 182874 and L-749329 were obtained in saphenous vein and cor-
onary artery. In vein Ro462005 (3, 10, 30 μM) had KB=5.65±0.07
(slope=1.05±0.19, n=4–5) and in artery KB=5.87±0.15
(slope=1.21±0.38, n=4–5). For bosentan (0.3, 1, 3, 10, 30 μM)
values in vein were KB=5.80±0.25 (slope=0.96±0.39, n=3) and
in coronary artery KB=5.53±0.17 (slope=0.91±0.30, n=3–5).
BMS 182874 (1, 3, 10 μM) in saphenous vein KB=6.56±0.10
(slope=0.94±0.32, n=3–6) and in coronary artery KB=6.18±
0.09 (slope=0.94±0.24, n=4–8). L-749329 (30, 100, 300 nM) had
KB=8.19±0.17 (slope 0.68±0.44, n=6–7) in vein and KB=7.91±
0.09 (slope 1.19±026, n=4–9) in artery. Afﬁnity for sitaxentan
(1, 3, 10 μM) was determined in saphenous vein; KB=7.21±0.16
(slope=1.10±0.50, n=7–9).
Carboxylic acid antagonists: For SB209670 (0.1, 0.3, 1, 3 μM) in sa-
phenous vein KB=7.93±0.19 (slope=0.79±0.19, n=3) and similar
afﬁnity was obtained in coronary artery (0.1, 0.3, 1 μM) KB 7.70±0.15
(slope=0.61±0.35, n=3–5). In contrast to its subnanomolar afﬁnity
determined for the cardiac ETA receptor in saphenous vein in binding
assays ambrisentan (0.3, 3, 10 μM)was amuch less effective antagonist
of ET-1 vasoconstriction than expected with KB=6.76±0.15 (slope=
0.69±0.23, n=6–7).
Myceric acid antagonists: For S97-139 (10, 30, 100 and 300 nM) in
saphenous vein KB=7.97±0.16 (slope=0.7±0.3, n=3–6) and in
coronary artery KB=7.61±0.12 (slope=0.70±0.27, n=3–4).
Discussion
The aim of our investigation was to address the question of whether
values of antagonist afﬁnity and receptor subtype selectivity, obtained
from cloned human receptors (Aramori et al., 1993; Breu et al., 1993;
Clozel et al., 1994; Doherty et al., 1993; Elliott et al., 1994; Fujimoto et al.,
1992; Mihara et al., 1994; Patt et al., 1997; Walsh et al., 1994; Webb et al.,
1995;Williamset al., 1993;Wuetal., 1997;Vatter andSeifert, 2006)predict
those obtained in human tissues that express both receptor subtypes
(Davenport and Russell, 2001) andwhich are the intended target for endo-
thelin antagonists clinically; speciﬁcally the heart (Love et al., 2000; Peter
and Davenport, 1995, 1996), lungs (Davie et al., 2009; Dupuis and
Hoeper, 2008; Liu et al., 2009; McLaughlin et al., 2009; Vachiery and
Davenport, 2009), kidney (Karet and Davenport, 1996; Kuc et al., 1995;
Goddard et al., 2004; Karet et al., 1993; Kohan, 1997, 2010; Longaretti and
Benigni, 2009; Neuhofer and Pittrow, 2009) and vasculature (Abraham
and Dashwood, 2008; Bacon and Davenport, 1996; Davenport and
Maguire, 1994, 2006; Davenport et al., 1995; Maguire and Davenport,
1995). We focussed on human heart as ET receptor sub-types are presentin the left ventricle in a ratio of about 60% ETA:40% ETB which allows for
the accurate measurement of afﬁnity constants for antagonists against
both receptors in the same experiments (Davenport and Kuc, 2005;
Molenaar et al., 1993; Peter and Davenport, 1995, 1996). We also deter-
mined afﬁnities (KD) in competition experiments in humanvascular tissues
(coronary artery and saphenous vein) (Bacon and Davenport, 1996;
Davenport et al., 1995; Maguire et al., 1994) for comparison to their afﬁni-
ties (KB) determined from the antagonism of ET-1 mediated vasoconstric-
tion in rings of these blood vessels in organ bath experiments (Davenport
and Maguire, 1994; Maguire, 2002; Maguire and Davenport, 1995;
Maguire et al., 1994, 1996, 1997). We identiﬁed a number of antagonists,
belonging to different structural classes; peptides, sulphonamides, car-
boxylic and myceric acids (Palmer, 2009) that included both the
reported ETA selective and mixed receptor antagonists. We have
summarised the data reported in the present study together with
human data that we have previously reported for antagonists from the
four classes and compared these values to those reported in the litera-
ture using human cloned receptors (Table 1). From this it is apparent
that the degree of selectivity for those antagonists in the peptide, sul-
phonamide and carboxylic acid classes, reported to be ETA selective
(BQ123, FR139317, sitaxentan, BMS 182874, PD156707, ambrisentan)
was markedly increased from ~200–7500 fold in cloned receptor cell
systems to ~800–200,000 fold in the human left ventricle binding
assay. As expected, those antagonists that had been reported to be
mixed antagonists (ETA selectivity b100, PD142893, Ro462005,
bosentan, L-749329, SB209670), we found that these compounds did
not distinguish between the two receptors in the human heart
(Table 1). The myceric acid antagonists were the only group in which
selectivity was as good or better in cloned receptors compared to native
receptors. Differences in assay conditions such as receptor over-expression
and co-expression with non-physiologically relevant G-proteins may ex-
plain some of the observed discrepancies. In some cloned receptor studies
different radioligands, [125I]-ET-1 or [125I]-ET-3, were used to label the
two subtypes ETA and ETB receptors respectively, whereas we used [125I]-
ET-1 to label both populations of receptor subtypes in the human left ven-
tricle. Agonist dependence of antagonist afﬁnity has been reported for some
endothelin antagonists andmay contribute, at least in part, to our observed
discrepancies.
If selective blockade of the vascular ETA receptor is clinically desir-
able how predictable of functional potency is the afﬁnity of an antag-
onist determined in a receptor binding assay? To address this
question we have carried out additional experiments to measure
how well the ETA afﬁnity of selective and mixed antagonists, deter-
mined in binding experiments, reﬂects their potency as functional an-
tagonists at the ETA receptor in vitro. We carried out Schild analysis of
data obtained from the antagonism of ET-1 induced vasoconstriction
in human isolated coronary artery and/or saphenous vein (an ETA re-
sponse (Davenport and Maguire, 1994; Maguire and Davenport,
1995)) for representative antagonists from each structural group
and have summarised these together with the data previously
reported for additional antagonists from the four groups in these
human tissues (Table 2). The Schild-derived afﬁnity values (ETA KB)
and the ETA afﬁnity (KD) determined in binding experiments in the
same vascular tissues were compared and expressed as a KB/KD
ratio (Table 2). These data indicated that for the peptide antagonists
concentrations required to block ET-1 vasoconstriction were 100–2000
fold higher than predicted by their ETA binding afﬁnity determined in
competition binding experiments in the same tissues using [125I] ET-1.
For the non-peptide antagonists the degree of KD to KB discrepancy
was much more variable; ranging from ten fold higher afﬁnity in func-
tional compared to binding assays (L-749329) to 1000 fold lower afﬁnity
determined in functional compared to binding assays (bosentan). Over-
all there was no apparent correlation between structural class and the
discrepancy in KB and KD values determined in the two assay systems.
Therefore, if these data are to be extrapolated to the clinical setting for
some antagonists, such as bosentan, the concentration required to
Table 2
Summary of ETA receptor afﬁnities reported for endothelin antagonists determined in
binding and functional assays in human coronary artery and saphenous vein.
Antagonist Vascular preparation Binding Functional
ETA KD ETA KBa KB/KD
Peptides
BQ123 Saphenous vein 0.55±0.17 nM1 141 nM2 256
Coronary artery 0.85±0.03 nM1 91 nM2 107
FR139317 Saphenous vein 0.56±0.01 nM 87 nM2 156
Coronary artery 0.41±0.13 nM3 126 nM2 307
PD151242 Coronary artery 0.51±0.07 nM4 1.1 μM4 2157
Sulphonamides
Ro-462005 Saphenous vein 0.15±0.01 μM 1.4 μM 9
Coronary artery 0.19±0.04 μM3 2.4 μM 12
Bosentan Saphenous vein 32.2±3.2 nM 1.6 μM 50
Coronary artery 2.94±0.95 nM3 2.9 μM 967
BMS 182874 Saphenous vein 580±40 nM 275 nM 0.5
L-749329 Saphenous vein 66.7±7.5 nM 6.5 nM 0.1
Carboxylic acids
SB209670 Saphenous vein 11.2±1.4 nM 12 nM 1.1
PD156707 Saphenous vein 0.5±0.13 nM5 2 nM5 4
Coronary artery 0.15±0.06 nM5 8 nM5 40
Myceric acids
50235 Coronary artery 6.8±2.9 nM6 1.1 μM6 157
New data are indicated in bold to distinguish from previously published data. ND. Not
determined.
KD — the equilibrium dissociation constant of a ligand determined by means of a
radioligand binding assay.
KB — the equilibrium dissociation constant of a competitive antagonist determined by
means of a functional assay.
KB/KD — the ratio of the equilibrium dissociation constant determined for a ligand in
functional compared to that obtained in radioligand binding experiments in the same
tissue.
1Davenport et al. (1995), 2Maguire and Davenport (1995), 3Bacon and Davenport
(1996), 4Davenport et al. (1994), 5Maguire et al. (1997), 6Maguire et al. (1994).
a KB derived from Schild data with slope constrained to one or from Gaddum–Schild
equation.
Table 1
Summary of endothelin receptor subtype afﬁnity and selectivity of antagonists reported for human left ventricle compared to values reported for human cloned receptors.
Antagonist Cloned receptorsa Human left ventricle
Ki ETA Ki ETB ETA selectivity KD ETA KD ETB ETA selectivity
Peptides
BQ123 17 nM 11.1 μM 6531 0.73±0.22 nM 24.3±2.0 μM 33,2882
FR139317 1 nM 7.3 μM 73003 1.20±0.28 nM 287±93 μM 239,1674
PD151242 ND 7.21±2.80 nM 104±23 μM 14,4245
PD142893 31 nMa,b 54 nMa,b 1.76 0.30±0.03 μM 1.17±0.14 μM 4
Sulphonamides
Ro-462005 360 nMb 530 nMb 1.57 One site ﬁt 50.3±9.5 μM4 Non-selective4
Bosentan 4.7 nM 95 nM 208 One site ﬁt 77.6±7.9 nM4 Non-selective4
Sitaxentan 1.4 nMb 9.8 μMb 70009 1.65±0.80 nM 327±134 μM 198,182
BMS 182874 48 nM >50 μM >104210 590±100 nM Not detectable >10,000
L-749329 0.6 nM 12 nM 2011 One site ﬁt 303.5±34.3 nM Non-selective
Carboxylic acids
SB209670 0.43 nM 14.7 nM 3412 One site ﬁt 0.67±0.14 nM Non-selective13
PD156707 0.3 nMb 780 nMb 260014 0.92±0.38 nM 13.3±2.1 μM 14,45715
Ambrisentan 1 nM 195 nM 19516 0.28±0.23 nM 0.25±0.05 μM 893
Myceric acids
50235 81 nM Inactive >100017 162±61 nM 171±42 μM 10564
S97-139 1 nM 1000 nM 100018 45.3±25 nM 47.6±9.9 μM 1051
ND Not reported. New data from this study are indicated in bold to distinguish from previously published data. Ki — the equilibrium dissociation constant of a ligand determined in
inhibition studies; KD — the equilibrium dissociation constant of a ligand.
1Williams et al. (1993), 2Molenaar et al. (1993), 3Aramori et al. (1993), 4Peter and Davenport (1996), 5Peter and Davenport (1995), 6Doherty et al. (1993), 7Breu et al.
(1993), 8Clozel et al. (1994), 9Wu et al. (1997), 10Webb et al. (1995), 11Walsh et al. (1994), 12Elliott et al. (1994), 13Johnström et al. (2004), 14Patt et al. (1997), 15Maguire et al.
(1997), 16Riechers et al. (1996), 17Fujimoto et al. (1992), 18Mihara et al. (1994).
a Or cells/animal tissues that endogenously express one receptor subtype exclusively or predominantly.
b IC50 value.
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much greater than predicted by in vitro binding assays.Whilst this is not
necessarily a problem for compounds that are either non-selective or
have a very marked ETA selectivity it may mean that those compounds
that have a more marginal ETA selectivity will have to be administered
at doses at which ETB occupancy becomes apparent and so these com-
pounds will not behave as selective ETA antagonists at clinically effec-
tive doses. The reason for the discrepancy in afﬁnities determined in
the binding and functional assays remains unclear. We have previously
reported that the afﬁnity of BQ123 for the ETA receptor determined in
competition binding assays using either [125I]ET-1 or [125I]sarafotoxin
6b (S6b) in human saphenous vein homogenates was identical but
the afﬁnity of BQ123 for ETA receptors determined in vasoconstrictor
studies in isolated saphenous vein depended on the agonist used
(Maguire et al., 1996). For S6b there was little discrepancy between
KD and KB whereas the afﬁnity of BQ123 in the functional assay was
250 times lower than predicted from the binding assay. This observa-
tion of agonist dependence of antagonist afﬁnity in functional assays
has beenwell documented, at least for some endothelin receptor antag-
onists (see for example Hay and Luttmann, 1997) suggesting that at
least some of these compounds may be negative allosteric modulators
of endothelin receptors rather than neutral competitive antagonists.
For the most part endothelin antagonists are not routinely screened
for activity against a number of agonists in binding and particularly
functional assays and therefore more data are required to determine
whether ligand dependence is common for the currently available
structural classes of endothelin antagonist.Conclusions
The differential distribution and function of ET receptor sub-types
(Davenport and Russell, 2001) provide the rationale for using two
distinct pharmacological strategies, mixed or ETA selective antago-
nism. Our study indicates that whilst antagonists reported to be ETA
685J.J. Maguire et al. / Life Sciences 91 (2012) 681–686selective in cloned human receptor systems generally show an even
greater degree of selectivity for ETA receptors in human tissues, for
some compound concentrations required to block ET-1 mediated
functional responses, such as vasoconstriction, are much greater
than predicted by binding experiments. Therefore, in order to test
the hypothesis of whether selective ETA, rather than mixed receptor
blockade is sufﬁcient for clinical beneﬁt, antagonists such as
ambrisentan and sitaxentan which display at least 1000 fold ETA
selectivity may be required to address this question in in vivo
investigations.
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